NCT02681549View on ClinicalTrials.gov

Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

May 1, 2016

Primary Completion Date

September 11, 2024

Study Completion Date

March 31, 2025

Conditions
MelanomaNon-small Cell Lung CancerBrain Metastasis
Interventions
DRUG

Pembrolizumab plus Bevacizumab

Pembrolizumab will be administered on day 1 of every cycle until disease progression or withdrawal from study. Bevacizumab will be administered in addition to pembrolizumab on day 1 of cycles 1, 2, 3, and 4 (or alternative cycles if bevacizumab is held during these cycles). Three weeks constitutes one cycle.

Trial Locations (2)

33612

Moffitt Cancer Center, Tampa

06510

Smilow Cancer Hospital at Yale New Haven, New Haven

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Yale University

OTHER

NCT02681549 - Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter